國立虎尾科技大學 |

Resistance to Targeted Therapies in Lymphomas

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Resistance to Targeted Therapies in Lymphomas / edited by Ana C. Xavier, Mitchell S. Cairo.
其他作者:	Xavier, Ana C.
面頁冊數:	XX, 210 p. 27 illus., 26 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cancer research. -
電子資源:	https://doi.org/10.1007/978-3-030-24424-8
ISBN:	9783030244248

Resistance to Targeted Therapies in Lymphomas
Resistance to Targeted Therapies in Lymphomas [electronic resource] /edited by Ana C. Xavier, Mitchell S. Cairo. - 1st ed. 2019. - XX, 210 p. 27 illus., 26 illus. in color.online resource. - Resistance to Targeted Anti-Cancer Therapeutics,212196-5501 ;. - Resistance to Targeted Anti-Cancer Therapeutics,4.

Mechanisms of Glucocorticoid Response and Resistance in Lymphoid Malignancies -- Resistance to Monoclonal Antibody Therapeutics in Lymphoma -- Resistance to Antibody-Drug Conjugate -- Resistance to Proteasome Inhibitor Therapy in Non-Hodgkin Lymphoma -- Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma -- Resistance to Bruton’s Tyrosine Kinase Signaling Pathway Targeted Therapies -- Resistance to Checkpoint Blockade Inhibitors and Immunomodulatory Drugs -- Resistance to Bispecific T-cell Engagers and Bispecific Antibodies -- Resistance to Chimeric antigen receptor T-cell therapy -- Index.

This volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era. .

ISBN: 9783030244248

Standard No.: 10.1007/978-3-030-24424-8doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Resistance to Targeted Therapies in Lymphomas
LDR:02898nam a22004095i 4500 001 1013623
003 DE-He213
005 20200703134859.0
007 cr nn 008mamaa
008 210106s2019 gw | s |||| 0|eng d
020 $a 9783030244248 $9 978-3-030-24424-8
024 7 $a 10.1007/978-3-030-24424-8 $2 doi
035 $a 978-3-030-24424-8
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Resistance to Targeted Therapies in Lymphomas $h [electronic resource] / $c edited by Ana C. Xavier, Mitchell S. Cairo.
250 $a 1st ed. 2019.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a XX, 210 p. 27 illus., 26 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Resistance to Targeted Anti-Cancer Therapeutics, $x 2196-5501 ; $v 21
505 0 $a Mechanisms of Glucocorticoid Response and Resistance in Lymphoid Malignancies -- Resistance to Monoclonal Antibody Therapeutics in Lymphoma -- Resistance to Antibody-Drug Conjugate -- Resistance to Proteasome Inhibitor Therapy in Non-Hodgkin Lymphoma -- Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma -- Resistance to Bruton’s Tyrosine Kinase Signaling Pathway Targeted Therapies -- Resistance to Checkpoint Blockade Inhibitors and Immunomodulatory Drugs -- Resistance to Bispecific T-cell Engagers and Bispecific Antibodies -- Resistance to Chimeric antigen receptor T-cell therapy -- Index.
520 $a This volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era. .
650 0 $a Cancer research. $3 1253664
650 1 4 $a Cancer Research. $3 668358
700 1 $a Xavier, Ana C. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1307884
700 1 $a Cairo, Mitchell S. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1307885
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030244231
776 0 8 $i Printed edition: $z 9783030244255
776 0 8 $i Printed edition: $z 9783030244262
830 0 $a Resistance to Targeted Anti-Cancer Therapeutics, $x 2196-5501 ; $v 4 $3 1254768
856 4 0 $u https://doi.org/10.1007/978-3-030-24424-8
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)